Review of MOA and Effectiveness of Current Treatments

Opinion
Video

Hematologic oncologists review therapeutic options for patients with chronic GVHD and provide clinical insights on their treatment approaches.

Video content above is prompted by the following questions:

  • Please discuss the effectiveness of the most used systemic treatment options.
    • How do you sequence treatments for chronic GVHD?
  • What are the most pressing challenges faced by healthcare providers in effectively managing cGVHD, particularly in patients who have progressed through multiple treatment lines?
Related Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Guillermo Garcia-Manero, MD, an expert on MDS
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content
A Deep Dive Into the FDA Approval of Imetelstat in Lower-Risk MDS

A Deep Dive Into the FDA Approval of Imetelstat in Lower-Risk MDS

Jordyn Sava
July 1st 2024
Article

Mikkael A. Sekeres MD, MS, further discussed the approval of imetelstat for the treatment of patients with low- to intermediate-1 risk myelodysplastic syndromes.

Read More

Cost Savings Associated with Zanubrutinib Over Acalabrutinib in B-Cell Malignancies

Cost Savings Associated with Zanubrutinib Over Acalabrutinib in B-Cell Malignancies

Chris Ryan
June 28th 2024
Article

Zanubrutinib treatment resulted in £599,000 cost savings and 3.7 QALY savings compared with acalabrutinib for 1000 hypothetical patients.

Read More

Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS

Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS

Targeted Oncology Staff
June 27th 2024
Article

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.

Read More

FLT3 Inhibitors Offer Benefit in AML Post Transplant

FLT3 Inhibitors Offer Benefit in AML Post Transplant

Tony Berberabe, MPH
June 26th 2024
Article

In general, mutations can occur in several genes in cytologically normal AML cells, including NPM1, FLT3, CEBPA, MLL, NRAS.

Read More

Following FDA’s Call for CAR T Boxed Warnings, Questions About Secondary Cancers Linger

Following FDA’s Call for CAR T Boxed Warnings, Questions About Secondary Cancers Linger

Sabrina Serani
June 25th 2024
Article

Secondary malignancies following CAR T-cell therapy have been a known risk, but an FDA investigation and call for labeling change have renewed interest.

Read More

SLS009 Scores Rare Pediatric Disease Designation in ALL

SLS009 Scores Rare Pediatric Disease Designation in ALL

Jordyn Sava
June 24th 2024
Article

The FDA granted a rare pediatric disease designation to a promising new drug, SLS009, for the treatment of pediatric leukemia.

Read More